Clinical efficacy of combining fenofibrate with statins in patients with diabetes and hyperlipidemia: a meta-analysis
-
By
-
March 25, 2026
Objective:
To systematically assess the clinical effectiveness of combining fenofibrate with statins in treating patients with diabetes mellitus and hyperlipidemia.
Key Findings:
- The combination therapy showed a higher overall efficacy rate (OR = 5.42, 95% CI = 3.11 to 9.45, P < 0.00001).
- Significant reductions in total cholesterol (SMD = -1.01, 95% CI = -1.60 to -0.41), triglycerides (SMD = -0.94, 95% CI = -1.59 to -0.30), and low-density lipoprotein cholesterol (SMD = -2.26, 95% CI = -3.05 to -1.47) were observed.
- Improvements in fasting plasma glucose (SMD = -0.37, 95% CI = -0.51 to -0.23) and postchallenge plasma glucose (SMD = -0.88, 95% CI = -1.19 to -0.57) levels were statistically significant.
Interpretation:
The combination of fenofibrate and statins is more effective than statin monotherapy in improving lipid and glycemic profiles in diabetic patients with hyperlipidemia.
Limitations:
- Long-term benefits on cardiovascular outcomes remain unconfirmed.
- Potential increased risk of adverse reactions such as muscular and hepatic events, which require careful monitoring.
Conclusion:
While fenofibrate and statin combination therapy is effective for lipid and glycemic control, careful monitoring and risk-benefit analysis are essential for clinical application.
